Cyclophosphamide Therapy
- 1 September 1961
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 108 (3) , 456-482
- https://doi.org/10.1001/archinte.1961.03620090128016
Abstract
Since 1946 when mechlorethamine hydrochloride (nitrogen mustard), an alkylating agent, was first reported to exert a suppressive effect on rapidly dividing cells,1many new alkylating agents have been synthesized. A few have weathered clinical trial and have proven their effectiveness in the control of chronic leukemias and lymphomas and palliation of patients with malignant tumors. These include triethylene melamine (T.E.M.), triethylene thiophosphoramide (thio-TEPA) and chlorambucil (Leukeran). Recently Arnold, Bourseaux, and Brock2reported the development of a new alkylating agent, cyclophosphamide*(N,N-bis (β-chloroethyl)-N,O-propylene phosphoric acid ester diamide monohydrate) which promised certain advantages over existing alkylating agents. Clinical trials conducted by Gross and Lambers3,4in Germany showed the beneficial effects in 9 of 23 patients with malignant lymphoma. Cyclophosphamide (Cytoxan*) was made available in this country for clinical trial in 1959. An early report by Coggins, Ravdin, and Eisman6suggested its continued appraisal inThis publication has 0 references indexed in Scilit: